Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Participants had ...

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. PSA is one of the most widely used and ...

A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer cell models in the ...

FORT MYERS, Fla., April 28, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Director of Drug Development Manish Patel, MD, was the oral presenter of an abstract ...

In a recent study published in the journal eBioMedicine, researchers attempted to identify, characterize, and quantify microplastics (including their abundances and types) found in human prostate ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer. McGill University researchers at the Rosalind and Morris Goodman Cancer Institute (GCI ...

A team at the University of Cordoba and IMIBIC tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human ...

New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation – a key immune regulator suppressed in cancer – delivering stronger epigenetic effects than Paclitaxel or Rapamycin in ...

A new study from Cold Spring Harbor Laboratory Professor Lloyd Trotman and colleagues, published in Science, shows that menadione significantly slows prostate cancer growth in mice and in ...